Please login to the form below

Not currently logged in
Email:
Password:

RA Patients

This page shows the latest RA Patients news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos JAK contender scores in RA trial

Gilead and Galapagos JAK contender scores in RA trial

drugs to help patients with active RA who don’t respond adequately to current biologics. ... blocker Humira (adalimumab) in RA when it comes to clinical responses gauged by doctors and patients.

Latest news

  • AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

    Patients with RA reported an improvement in mobility pain on the JAK1 inhibitor. ... AbbVie’s run of positive results for upadacitinib in rheumatoid arthritis continues with new data at EULAR on patients’ experience with the drug.

  • FDA panel undermines Lilly and Incyte’s baricitinib hopes FDA panel undermines Lilly and Incyte’s baricitinib hopes

    The panel gave its blessing to the lower 2mg dose of the JAK inhibitor for adult patients with moderately-to-severely active RA who don’t respond to or cannot tolerate ... Lilly has put a brave face on the outcome, saying that it is “confident that

  • AbbVie’s upadacitinib aces phase III trial AbbVie’s upadacitinib aces phase III trial

    III trial in rheumatoid arthritis patients, without adding to a tally of thrombotic side effects. ... The results were achieved in patients with moderate-to-severe RA who were being treated with methotrexate but whose symptoms were not being controlled.

  • AbbVie’s JAK inhibitor upadacitinib clears another phase III trial AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

    symptoms and dampening down disease activity in RA patients compared to prior stable methotrexate therapy in the SELECT-MONOTHERAPY study. ... Its earlier trials in RA have compared the drug to placebo on top of methotrexate therapy.

  • Boehringer claims EU okay for Humira biosimilar Boehringer claims EU okay for Humira biosimilar

    Earlier this month Boehringer reported the results of the VOLTAIRE-RA in patients with moderate-to-severe rheumatoid arthritis, showing that Cyltezo was equivalent to $16bn-a-year Humira - the ... Nevertheless, the approval “marks a significant step

More from news
Approximately 0 fully matching, plus 60 partially matching documents found.

Latest Intelligence

  • Pharma deals during February 2014 Pharma deals during February 2014

    Novo Nordisk conducted a phase I safety trial with anti-NKG2A in patients with RA, and will be advancing further development in inflammation, including anti-NKG2D1, which is currently undergoing phase ... paid on an instalment plan based on future revenue

  • Seeking improvements

    Published: 30 Nov 2011. Two surveys were conducted to assess how policy developments had changed RA services. ... priorities for supporting and treating patients with RA.

  • Bright rheumatology future

    Communicate the main findings and outcomes of research project. •   Drive awareness of RA. ... More than 50 stakeholders participated in the development of the pathway, including nurses, commissioners and RA patients.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Biosimilars in 2018: EU doctors’ perceptions of RA drug market

    A panel of around 200 physicians treating RA across Europe (France, Germany, Italy, Spain and the UK) were asked how they currently treat their patients and what they expect to be ... www.researchpartnership.com/news/2015/10/article-biosimilars-in-2018-ra

  • Infographic: RA Perceptions

    expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ ... Download our RA Perceptions: Predicting the future of

  • Infographic: RA market snapshot

    An overview of the RA biologic patient. Our RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents.

  • Removing the Roadblocks to Effective Patient Treatment

    However, we found RA patients wait an average of 18 months before presenting to a doctor. ... Roadblock 2: Diagnosis – Poor doctor relationship and ongoing anxiety. The relationship RA patients have with their rheumatologist is crucial in getting them

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics